KLOW Blend
GHK-Cu 50 mg, BPC-157 10 mg, TB-500 (thymosin beta-4) 10 mg and KPV 10 mg, co-lyophilized in one vial. Every lot is tested in the manufacturer’s own laboratory, with a certificate confirming all four components.
| Components | GHK-Cu (Copper tripeptide-1; Gly-His-Lys · Cu(II))BPC-157 (Body Protection Compound-157; pentadecapeptide)TB-500 (Thymosin β4); N-acetyl thymosin β4, full-length 43-residue peptideKPV (Lys-Pro-Val; α-MSH(11–13)) |
|---|---|
| GHK-Cu CAS number | 89030-95-5 |
| BPC-157 CAS number | 137525-51-0 |
| TB-500 (Thymosin β4) CAS number | 77591-33-4 |
| KPV CAS number | 67727-97-3 |
| Label claim | GHK-Cu 50 mg + BPC-157 10 mg + TB-500 (Thymosin β4) 10 mg + KPV 10 mg (80 mg in total) |
| Form | Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap |
| Storage, sealed | −20 °C, desiccated, dark |
| Purity specification | 99.0% or higher by RP-HPLC |
| Format | Lyophilized powder, sealed vial |
Sizes and lots
- 80 mg · 1 vial — $107.00 · lot PL-2609-057, certificate PL-26-00057
- 80 mg · Kit of 10 — $959.00 · lot PL-2609-057, certificate PL-26-00057
KLOW is a four-peptide research blend: the copper complex GHK-Cu, the gastric pentadecapeptide BPC-157, full-length thymosin beta-4 sold as TB-500, and the tripeptide KPV. This listing is the 80 mg vial, the four freeze-dried together into one blue cake at 50, 10, 10 and 10 mg. No published study has examined KLOW, or any mixture of these four, as a blend, so the research summarised here is the separate literature on each component.
What is in the vial
The certificate lists four sequences and confirms all four by LC-MS: GHK-Cu (H-GHK-OH with one Cu(II), 401.9 Da), BPC-157 (H-GEPPPGKPADDAGLV-OH, 15 residues, 1419.6 Da), TB-500 as full-length N-acetyl thymosin beta-4 (43 residues, 4963.5 Da) and KPV (H-KPV-OH, 342.4 Da). GHK-Cu makes up 50 of the 80 mg. Counted in molecules it dominates further, because it is small: 50 mg is about 124 µmol, against roughly 29 µmol of KPV, 7.0 µmol of BPC-157 and 2.0 µmol of thymosin beta-4. That is about sixty GHK-Cu molecules for each thymosin beta-4 molecule.
The cake and its solutions are blue because of the copper complex. KLOW is the GLOW 70 mg composition with 10 mg of KPV added, and the GKP blend is this vial without TB-500. The same four peptides are sold already dissolved in the KLOW pen.
What the research covers
KLOW is a supplier-defined combination. No paper characterises it as a blend, and none has given these four peptides together to cells or animals, so there is no evidence on how they act in combination or whether one changes the behaviour of another. What exists is four separate bodies of work, of very different depth.
GHK-Cu
GHK is a plasma tripeptide with an affinity for copper(II)1. In fibroblast cultures its copper complex raised collagen synthesis from picomolar concentrations, peaking at 1 nanomolar, without any change in cell number1. The authors noted that the GHK sequence sits inside type I collagen and suggested that proteases at a wound might release it1.
BPC-157
BPC-157 is a 15-residue partial sequence of a protein found in human gastric juice2. Much of its literature comes from Sikiric's group in rats, whose 2011 review reported protection against lesions along the gastrointestinal tract, from esophagitis and stomach injury to fistulas and intestinal anastomoses, along with angiogenic and endothelium-protective effects3. Two mechanistic studies from other groups worked in cells. Hsieh and colleagues found that BPC-157 increased vessel density in the chick chorioallantoic membrane and in endothelial tube assays, sped the return of blood flow in ischemic rat hind limbs, and raised VEGFR2 but not VEGF-A in human vascular endothelial cells, where it activated VEGFR2-Akt-eNOS signalling4. Chang and colleagues reported faster outgrowth from rat Achilles tendon explants and more migration, spreading and stress survival in tendon fibroblasts, with no direct effect on proliferation and with increased phosphorylation of FAK and paxillin2.
TB-500 (thymosin beta-4)
The TB-500 in KLOW is the complete 43-residue thymosin beta-4. Inside cells the beta-thymosins are the main peptides that sequester G-actin: each binds one actin monomer, holding it out of filaments while keeping a pool ready for when the cell needs to build them5. Thymosin beta-4 is also found in blood plasma and wound fluid, and effects attributed to it there include chemotaxis, angiogenesis and reduced inflammation5.
KPV
KPV (Lys-Pro-Val) corresponds to residues 11 to 13 of alpha-melanocyte-stimulating hormone. In human intestinal epithelial cell lines and T cells stimulated with pro-inflammatory cytokines, nanomolar KPV inhibited activation of NF-κB and MAP kinase signalling and reduced cytokine secretion6. The same study asked whether that effect depended on uptake through PepT1, a di- and tripeptide transporter induced in the colon during inflammatory bowel disease, and examined KPV in two mouse colitis models6.
What is not established
Nothing is known about the four together: whether they interact in solution, whether the copper complex affects the other peptides, or whether any combined effect differs from the sum of the parts. The component evidence itself is mostly cell and rodent work. The BPC-157 animal literature leans heavily on one research group, and its 2011 review describes the peptide as safe in inflammatory bowel disease trials without giving results3. For thymosin beta-4, Huff and colleagues wrote that nothing was known about the mechanisms behind its effects outside cells5. None of the studies used SCALE Performance material. The KLOW peptide guide walks through each component in more detail.
Frequently asked questions
What exactly is in the KLOW blend?
Four peptides freeze-dried together in one vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg, 80 mg in all. The TB-500 is full-length N-acetyl thymosin beta-4. The lot certificate confirms each of the four by LC-MS and reports purity by RP-HPLC.
How does KLOW differ from GLOW and GKP?
All three are built on 50 mg of GHK-Cu with 10 mg portions of other peptides. GLOW 70 mg adds BPC-157 and TB-500; KLOW adds KPV to that; GKP keeps KPV and BPC-157 but drops TB-500. GLOW 50 mg is a separate product with its own ratio.
Has the KLOW blend itself been studied?
No. No published study has tested KLOW, or these four peptides combined, in cells, animals or people. The research on this page describes each component on its own, and any claim about what the blend does as a whole goes beyond the evidence.
Why is the powder blue?
Because of GHK-Cu. The copper(II) ion bound in that complex gives the cake its colour, and reconstituted solutions are blue as well. The other three peptides are white powders on their own, but at 50 of the 80 mg the copper complex sets the colour of the whole vial.
How should the vial be stored?
Sealed, at −20 °C, desiccated and dark. Warm it to room temperature before opening to avoid condensation. After reconstitution keep the solution at 2 to 8 °C away from light and use it within a period your laboratory has established, since no stability data have been published for the four together in solution.
References
- Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. DOI · PubMed
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. DOI · PubMed
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. DOI · PubMed
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. DOI · PubMed
- Huff T, Müller CS, Otto AM, et al. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-20. DOI · PubMed
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. DOI · PubMed
For laboratory research use only. Not for human or veterinary consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.